NME approvals up a tic in 2008

Share this article:
The FDA rang out 2008 with the approval of Ferring's degarelix, for prostate cancer, capping another slow year for new drug approvals.
The green light for degarelix followed delays in approvals on Takeda's Actos replacement alogliptin – for which the agency set a new target date of June 2009 – and AstraZeneca's Seroquel XR for major depressive disorder, for which FDA issued a complete response letter (nee “approvable letter”) last week.

An Associated Press analysis of agency approvals, published Dec. 19, counted 21 truly novel drugs approved in 2008 – up from 18 in 2004. The approval of degarelix would push it up to 22. Cold comfort for the many manufacturers that saw potentially pivotal drugs delayed as a cautious agency, still shell-shocked from Vioxx and under withering Congressional scrutiny on drug safety issues, demanded further information.

The AP analysis also said the under-resourced agency missed its target review dates for at least 15 drugs, as it did with alogliptin.

After several years of stagnation, the climate for new drug approvals could improve in 2009, with unified Democratic control of Congress and the White House giving the FDA a freer hand and the prospect of a permanent commissioner steering the often rudderless agency.  
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.